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Abstract Aldosterone is synthesised by aldosterone
synthase (CYP11B2). CYP11B2 has a highly homologous
isoform, steroid 11b-hydroxylase (CYP11B1), which is
responsible for the biosynthesis of aldosterone precursors
and glucocorticoids. To investigate aldosterone biosyn-
thesis and facilitate the search for selective CYP11B2
inhibitors, we constructed three-dimensional models for
CYP11B1 and CYP11B2 for both human and rat. The
models were constructed based on the crystal structure of
Pseudomonas Putida CYP101 and Oryctolagus Cuniculus
CYP2C5. Small steric active site differences between the
isoforms were found to be the most important determinants
for the regioselective steroid synthesis. A possible expla-
nation for these steric differences for the selective synthesis
of aldosterone by CYP11B2 is presented. The activities of
the known CYP11B inhibitors metyrapone, R-etomidate,
R-fadrazole and S-fadrazole were determined using assays
of V79MZ cells that express human CYP11B1 and
CYP11B2, respectively. By investigating the inhibitors in
the human CYP11B models using molecular docking and
molecular dynamics simulations we were able to predict a
similar trend in potency for the inhibitors as found in the
in vitro assays. Importantly, based on the docking and
dynamics simulations it is possible to understand the
enantioselectivity of the human enzymes for the inhibitor
fadrazole, the R-enantiomer being selective for CYP11B2
and the S-enantiomer being selective for CYP11B1.
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Introduction
Aldosterone is a member of the renin angiotensin aldo-
sterone system (RAAS) that plays an important physio-
logical role in the regulation of electrolyte homeostasis and
thereby blood pressure. This endogenous mineralocorticoid
exerts its function by binding to the mineralocorticoid
receptor. Upon ligand binding, the protein-ligand complex
is translocated to the cell nucleus, where it modulates the
gene expression of proteins involved in electrolyte
homeostasis [1]. Aldosterone is produced predominantly in
the adrenal cortex and is derived from cholesterol through
various steps involving a number of dehydrogenases and
cytochrome P450 enzymes (CYPs). This includes aldoste-
rone synthase (CYP11B2), which catalyses the ﬁnal steps
of aldosterone biosynthesis.
Recently, various studies on the pathophysiology of heart
failure have revealed that aldosterone plays a role in the
formation of myocardial hypertrophy, reactive myocardial
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This may contribute to the development of arrhythmias,
hypertension and congestive heart failure [2, 3]. Although
great therapeutic successes have been achieved by treating
heart failure patients with blockers of the RAAS (CON-
SENSUS trial [4], SOLVD trial [5]), the mortality due to
heart failure is still high. Therefore, exploring new thera-
peutic possibilities is highly desirable. Recently, it became
clear that aldosterone is also a key player in heart failure. In
the RALES study [6], blocking the action of aldosterone
using the mineralocorticoid receptor antagonist spirono-
lactone, proved to greatly reduce mortality, hospitalisation
numbers and hospitalisation time in patients with severe
heart failure. Later, similar encouraging results were found
for eplerenone, another mineralocorticoid receptor antago-
nist (EPHESUS trial [7, 8]), in patients with post myocar-
dial infarction. From this it can be derived that reducing
aldosterone action seems highly beneﬁcial in the treatment
of heart-failure and that it is particularly worthwhile to ﬁnd
new pharmacological manners to interfere with this
hormone.
An alternative manner to reduce aldosterone action
would be not to block the mineralocorticoid receptor, but to
prevent formation of the hormone itself by inhibiting its
biosynthesis [9]. Although the net outcome of aldosterone
receptor inhibition versus aldosterone synthesis inhibition
apparently is identical, a number of potential advantages
for the latter approach exists: reduction of side effects as
particularly observed for the antagonist spironolactone [6,
10], prevention of compensatory aldosterone synthesis
inherent to mineralocorticoid receptor blockade (of which
long term effects are unknown) [11, 12], and possible
circumvention of inter-individual variations regarding
pharmacodynamics and pharmacokinetics that are as ob-
served for mineralocorticoid receptor antagonists [13]. The
clinical use of inhibitors of aromatase (CYP19, which
converts androgens into estrogens) next to estrogen
receptor antagonists in the treatment of breast cancer, is
one of the examples that shows that the approach of ligand
synthesis inhibitors clinically can be of great use, despite
the existence of receptor blockers for that ligand [14, 15].
The last steps of the biosynthesis of aldosterone are
mediated by the mitochondrial cytochrome P450 11B
family (CYP11B) (Fig. 1). Members of this protein family
contain a heme prosthetic group in the core of the active site
with which they catalyse (subsequent) oxidation reactions
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Fig. 1 Biosynthesis of
Aldosterone by the CYP11B
family. Indicated with arrows
are the possible substrate
conversions performed by
human CYP11B1 and
CYP11B2 [19]. Rat CYP11B1
and CYP11B2 possess the same
activities as the human
isoforms, except that rat
CYP11B1 can also oxidise
11-deoxycorticosterone
on C19 [21]
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123on C11,C 18 and C19 on the b-side of the steroid skeleton (for
enumeration see Fig. 1). In bovine [16], pig [17] and frog
[18], aldosterone synthesis is performed by only one cyto-
chrome, CYP11B, but in human [19] and mouse [20] the
synthesis involves two isoforms, CYP11B1 (steroid 11b-
hydroxylase) and CYP11B2 (aldosterone synthase). Rat
possesses four isoforms for which CYP11B1 and CYP11B2
are the most important ones. CYP11B3 is only expressed in
neonatal rat and carries the same activity as CYP11B2, and
CYP11B4 encodes a pseudogene [21].
Most remarkable is the substrate speciﬁcity of the dif-
ferent isoforms. In both man and rat, only the CYP11B2
isoform can perform the ﬁnal oxidation of C18 to produce
aldosterone [19, 21]. For the CYP11B1 isoform, C19
hydroxylation has been reported for rat but not yet for man
[21], and the CYP11B1 isoform in general is known to play
an important role in the biosynthesis of glucocorticoids. If
an inhibitor of aldosterone synthesis is to be designed, the
biosynthesis of glucocorticoids should remain unaffected,
indicating that the inhibition must be CYP11B2 selective.
We developed three-dimensional in silico models as a
decision making tool to facilitate the selection of potential
CYP11B2 inhibitors for synthesis and in vitro testing. In
order to obtain speciﬁc CYP11B2 inhibitors, we also
investigated its highly homologous family member
CYP11B1.
The aim of this report is (1) to deduce by homology/
comparative modelling the architecture of CYP11B1 and
CYP11B2 around their active site, (2) to investigate pro-
tein-substrate interactions and propose a mechanism for
substrate regioselectivity and (3) to validate the homology
models by correlating the in vitro activity of four known
inhibitors to in silico data. The inhibitors we have chosen
are metyrapone [22], R-etomidate [23], R-fadrazole and
S-fadrazole [24] (Fig. 2). The in silico models not only
represent an important tool in modern drug discovery but
will also help in elucidating molecular mechanisms and
(substrate binding) preferences of the substrate conversion
of the enzymes of interest.
Modelling considerations
Homology modelling has been widely applied to the family
of cytochrome P450 enzymes and is mainly oriented to-
wards enzyme inhibition. Before the ﬁrst mammalian
cytochrome P450 structures became available, modelling
attempts were classically performed with crystal structures
possessing sequence identities lower than 25% because no
realistic alternatives were available. Homology models
were often based on a template of bacterial CYP101 [25–
27], but the introduction of bacterial CYP102 allowed for
modelling the functional properties of eukaryotic class II
P450s [28]. Although these homology models contain a
low sequence identity with their template structures and are
intuitively suboptimal, it has been shown that they can
describe key features of protein-ligand interactions [27,
28]. For example, features observed for inhibitor binding in
aromatase models have provided important insights for the
development of drugs [27, 29]. Current models often still
feature bacterial P450s as template [30, 31], but methods
involving the usage of multiple crystal structures for model
construction may prove to be the future trend [32, 33]. A
model based on the structure of several known enzymes
would be more accurate since every additional segment
will improve similarity or spatial coordination of protein
regions. However, structural ﬂaws can be expected at
locations where the template structures are joined and if
these regions are within the active site, they need to be
thoroughly reﬁned.
Some modelling work on CYP11B1 and CYP11B2 has
already been performed earlier by Belkina et al. [34] and
Ulmschneider et al. [35]. The models of Belkina et al.
discuss the potential spatial arrangement of the amino acids
in the active site and hypothesise the hydrogen-bonding
network involved in heme stabilisation. Furthermore, the
effect of several amino acid mutations have been detailed.
The models of Ulmschneider et al. focus on describing
protein-inhibitor interactions and structure activity rela-
tions of their developed inhibitors. The so far published
models were thoroughly characterised for those speciﬁc
purposes, however, the goal of our model construction
work was to investigate the regioselectivity of the natural
ligands within the enzymes and to detail potential protein-
ligand interactions.
For validation of our own three-dimensional models, the
in silico data are presented in the form of molecular
docking and molecular dynamics simulations. These
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Fig. 2 Chemical structures of the known CYP11B inhibitors,
metyrapone, R-etomidate, R-fadrazole and S-fadrazole
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123methods are regularly used to investigate protein-ligand
interactions. Because the only difference in the activity of
the two isoforms CYP11B1 and CYP11B2 is the formation
of aldosterone by the latter, successful 3D modelling of the
isoforms relies on a careful analysis of the speciﬁc sub-
strate conversion activities that exists between these two
isoforms.
Because of this we reviewed an experimental mutation
study by Bottner et al. [36] on the human CYP11B1 and
CYP11B2 proteins, performed in a similar manner as by
Belkina and Ulmschneider for the currently published
models [34, 35]. The study by Bottner et al. showed that
mutation of three residues outside the active site (L301P,
E302D, A320V) is sufﬁcient to convert the catalytic
activity of CYP11B2 into that of CYP11B1, suggesting
that remote steric aspects play a more important role in the
substrate binding and substrate conversion than the pres-
ence of different amino acids in the active sites of both
isoforms. This led us to postulate that the difference in
substrate conversion is caused by a difference in the rela-
tive positioning of the substrate above the heme in the
active site. To be more speciﬁc, we postulate that there is a
correlation between substrate selectivity and the substrate
hydroxylation distance, the distance between the heme iron
and the substrate carbon. In other words, the binding mode
of the natural substrate dictates which carbon atom is ox-
idised ﬁrst, with conversion taking place on the carbon
atom which is in closest proximity to the iron-oxygen
complex.
For human CYP11B1 this means that C11 and C18 are to
be in close proximity to the catalytic iron atom, with C11
closest to the iron. Rat CYP11B1 possesses a similar
binding mode, but we expect that it also presents C19 in a
position allowing oxidation. Explaining the preference for
C18-hydroxylation, human and rat CYP11B2 would bind
with C18 closest to the iron atom and C11 at a correct
distance for oxidation.
To substantiate this hypothesis, the three dimensional
architectures of the human and rat CYP11B enzymes were
constructed using comparative modelling. For reasons of
relevance only the CYP11B1 and CYP11B2 isoforms were
investigated. We intend to show how knowledge of these
various hydroxylation patterns of aldosterone precursors
can result in working models for the substrate selective
activity of the two isoforms. From here on, the human
isoforms will be noted as hCYP11B1 and hCYP11B2,
whereas the rat isoforms will be noted as rCYP11B1 and
rCYP11B2.
As stated above, another aim was to validate the
in silico models with in vitro activity data of four known
inhibitors. These inhibitors were chosen for the following
reasons. Metyrapone is a known inhibitor of CYP11B1 and
is clinically used in the diagnosis of Cushing Syndrome
[22, 37]. R-etomidate is clinically used as anaesthetic, but it
is known to be a highly potent suppressor of the CYP11B
family [23, 38]. Racemic fadrazole was designed for the
selective inhibition of aromatase, a cytochrome P450 en-
zyme which is closely related to the CYP11B family be-
cause it oxidises steroids on C19. Next to aromatase
inhibition, racemic fadrazole also shows considerable
inhibition of members of the CYP11B family [24, 39].
Methods
Homology modelling
The amino acid sequences of the CYP11B family were
taken from Swissprot [40] (hCYP11B1 accession P15538,
hCYP11B2 accession P19099, rCYP11B1 accession
P15393, rCYP11B2 accession P30099, rCYP11B3 acces-
sion P30100) and the determination of the secondary
structures of the CYP11B family members was performed
using the secondary structure prediction program JPred
[41]. The alignment used for homology modelling was
obtained with MOE-Align [42] by performing a topological
alignment of the cytochrome P450 enzymes for which a
crystal structure is publicly available (Fig. 3). The three
dimensional architecture of cytochrome P450 enzymes
consists of 12 alpha-helices annotated from A to L, as well
as six beta-sheets, despite having a sequence identity
among P450s less than 20%. Additionally, several short
helices are present in various cytochrome P450 enzymes
(annotated B¢,F ¢,G ¢,J ¢,K ¢) whilst being absent in others.
The structural core of all cytochrome P450 enzymes con-
sists of a four-helix bundle composed of alpha-helices D,
E, I and L, and the two alpha-helices J and K. The variable
structural features involved in ligand binding and substrate
speciﬁcity are situated in alpha-helices A, B, B¢, F, G and
their adjacent loops [43–45].
The predicted secondary structures for the CYP11B
family members were aligned to these topological features
of the crystal structures, as well as by preserving several
characteristic CYP features [46]: W(R/K)XXR (X indicates
any amino acid) in helix C connecting and stabilising the
heme prosthetic group in the active site, EXXR in helix K
and (W/F)XXPXX(F/Y)XPX(H/R)(W/F) following helix
K¢ comprising the typical meander region, and ﬁnally
XXF(G/S)XGX(H/R)XCXGXX(L/F)AXXE before helix L
Fig. 3 Topology alignment of human and rat CYP11B isoforms to
related cytochrome P450 enzymes of which a three dimensional
structure has been elucidated. Indicated with a & are the Arg123 in
alpha-helix B¢ and Glu310 in alpha-helix I. Indicated with a * is the
triple mutant L301P, E302D, A320V in alpha-helix I. Indicated with a
^ is the catalytic Thr318 in alpha-helix I. Indicated with a # is the
conserved Glu459 in alpha-helix L
c
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123which contains the cysteine residue by which the heme
prosthetic group is bound to the enzyme. Furthermore, a
glutamic acid was aligned that is thought to be involved in
the formation of a catalytically important water channel
[47] (Glu366 in CYP101, Glu459 in the CYP11B family),
and the entire helix I was aligned for its catalytic threonine
(Thr252 in CYP101, Thr318 in CYP11B family) [47]. As a
result of small variations in loop regions, some insertions
and deletions were introduced in segments outside the ac-
tive site. These segments did not correspond to any of the
key secondary structures.
Clearly, CYP11B1 and CYP11B2 portray a high degree
of homology possessing a pair wise sequence identity
percentage as high as 94% for human and 83% for rat
(Table 1, highlighted). This emphasises the difﬁculty of
modelling the difference between the two isoenzymes and
the challenge of reaching the level of modelling accuracy
that is required. For P450 enzymes for which a crystal
structure is publicly available, the overall pair wise se-
quence identity with the CYP11B family is found to be less
than 20%, whereas it is around 30% for active site residues.
This low degree of homology indicates that none of the
reviewed cytochromes can be used as a sole representative
for modelling the CYP11B family.
Because of the low sequence identity of the CYP11B
family, we have chosen to create a hybrid template for
hCYP11B2 using MOE-Homology [42], constructed from
the crystal structures of CYP101 (pdb code: 2CPP) and
CYP2C5 (pdb code: 1NR6). Our criteria for using CYP101
and CYP2C5 involve similarity in functionality of both the
cytochrome P450 reduction system and ligand character-
istics, but importantly also involves the spatial positioning
of active site regions.
Thus far, all modelling attempts on cytochrome P450
family 11 have included the usage of microsomal P450s
such as CYP102 [30, 34] and CYP2C9 [35]. However, the
CYP11B family belongs to the bacterial/mitochondrial
cytochrome P450 class which obtains electrons from the
ferredoxin reductase family in the electron transfer chain
[48]. Using CYP101 for the modelling of mitochondrial
P450s is therefore more intuitive and has been successfully
applied to other mitochondrial P450s [33, 49].
The natural ligands of the CYP11B family are steroids,
and steroids can be substrates for hepatic cytochromes that
belong to the microsomal cytochrome P450 class. In
CYP2C5 and CYP2D6 steroids are oxidised on the b-side
of the steroid skeleton at carbon atoms close to C11 and C18
[50], and their crystal structures may possess the necessary
interaction features for model construction. However,
investigation of the crystal structure of CYP2D6 (PDB
code: 2F9Q) raised doubt on the appropriateness for its use
as a template structure. The crystal structure is resolved at
Table 1 Generic pair wise sequence identity (in percentages) between the human and rat CYP11B isoforms and cytochrome P450 enzymes for
which a three dimensional structure has been elucidated
Chains 101 102 107 108 119 55 51 2B4 2C5 2C8 2C9 2D6 3A4 h11B1 h11B2 r11B1 r11B2 r11B3
CYP101 – 17.3 30.2 37.7 39.6 38.5 23.5 21.2 23.1 30.8 23.1 11.5 19.6 26.4 24.5 24.5 26.4 26.4 2CPP
CYP102 16.3 – 24.5 28.3 39.6 19.2 29.4 26.9 34.6 30.8 32.7 14.8 47.1 26.4 26.4 24.5 24.5 24.5 1BU7
CYP107 20.0 12.3 – 28.3 50.9 36.5 21.6 19.2 21.2 21.2 25.0 14.3 21.6 20.8 18.9 20.8 18.9 18.9 1JIN
CYP108 23.2 15.8 22.1 – 35.8 28.8 29.4 25.0 26.9 28.8 25.0 17.9 29.4 26.4 26.4 28.3 28.3 28.3 1CPT
CYP119 18.8 16.0 25.6 20.8 – 34.6 27.5 28.8 28.8 32.7 28.8 25.0 29.4 26.4 26.4 28.3 26.4 26.4 1F4U
CYP55 21.2 11.2 28.5 24.7 24.3 – 19.6 17.3 19.2 21.2 23.1 18.5 19.6 18.9 17.0 17.0 17.0 17.0 1ROM
CYP51 12.3 18.0 19.1 17.2 14.7 16.0 – 23.1 28.8 25.0 25.0 11.1 35.3 20.8 20.8 17.0 20.8 20.8 1EA1
CYP2B4 14.6 16.7 16.4 14.0 15.0 16.0 16.7 – 57.7 65.4 59.6 33.3 33.3 32.1 32.1 32.1 30.2 30.2 1SUO
CYP2C5 16.8 17.8 16.6 14.8 16.9 15.0 14.9 51.0 – 69.2 78.8 44.4 33.3 32.1 32.1 28.3 32.1 32.1 1NR6
CYP2C8 15.8 17.6 16.4 15.5 15.8 15.8 13.4 53.8 73.6 – 69.2 44.4 31.4 30.2 30.2 30.2 30.2 30.2 1PQ2
CYP2C9 15.6 18.0 17.4 15.0 16.6 15.3 14.3 51.0 77.3 78.4 – 40.7 33.3 32.1 32.1 28.3 30.2 30.2 1OG2
CYP2D6 13.1 16.9 14.9 14.3 14.7 16.0 16.7 39.6 40.0 40.6 38.5 – 14.8 25.0 25.0 25.0 21.4 21.4 2F9Q
CYP3A4 14.1 22.0 19.6 14.5 17.2 14.8 16.5 22.8 22.0 22.9 21.9 17.9 – 32.1 32.1 30.2 30.2 30.2 1W0E
h11B1 16.0 16.3 14.6 15.5 16.1 12.0 14.9 17.4 17.6 15.8 17.3 14.9 17.1 – 98.1 81.1 86.8 84.9 –
h11B2 15.3 16.9 13.6 14.8 15.8 12.0 14.5 17.4 17.6 16.2 17.7 15.5 17.5 93.6 – 83.0 88.7 86.8 –
r11B1 12.3 15.4 13.2 13.8 15.3 11.0 13.4 17.4 16.7 16.6 17.7 14.4 17.3 63.6 63.6 – 88.7 86.8 –
r11B2 15.3 15.8 14.4 14.5 16.6 13.0 14.7 15.9 16.2 15.8 17.1 13.5 16.8 68.2 68.8 82.6 – 98.1 –
r11B3 15.4 15.8 14.4 14.5 16.6 13.0 14.7 15.9 16.2 15.8 17.1 13.8 16.8 68.6 69.2 83.0 97.3 – –
The bottom triangle indicates the pair wise sequence identity of the whole protein, the top triangle indicates the pair wise sequence identity of the
residues within 5.0 A ˚ from the surface of the active site cavity of CYP101. Species information: Pseudomonas-Putida 2CPP, Bacillus Mega-
terium 1BU7, Saccharopolyspora-Erythreaea 1JIN, Pseudomonas-SP 1CPT, Archaeon Sulfolobus Solfataricus 1F4U, Fusarium-Oxysporum
1ROM, Mycobacterium Tuberculosis 1EA1, Oryctolagus Cuniculus 1SUO and 1NR6, Homo Sapiens 1PQ2, 1OG2, 1W0E and 2F9Q
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123low resolution (3.0 A ˚) in a tetramer complex. In this
complex numerous amino acids participate in an extensive
interaction network between the monomers and the struc-
ture was therefore excluded from our modelling work. Of
the other hepatic P450 enzymes, CYP3A4 can also oxidise
steroids, but its oxidation sites are on the opposite side of
the steroid skeleton or on the different steroid rings. This
means that the steroids bind with a rotated or reversed
orientation in the active site [51], which may provide dif-
ferent active site conformation than the CYP11B family.
Furthermore, many CYP2D6 substrates are characterised
by a basic nitrogen [52], and the CYP2C9 substrates are
mostly weakly acidic [53]. These properties are found to be
less desirable for modelling of the CYP11B family than the
functionally similar properties of the cyclic alkane sub-
strates of CYP101. The structures of CYP2C9 also do not
provide information about the molecular basis of regiose-
lectivity of the substrate, since a conformational change of
the active site is required to allow the substrate hydroxyl-
ation sites to contact the heme [54]. Because of the dif-
ferent ligand properties, the structures of hepatic CYP2D6,
CYP2C9 and CYP3A4 were found to be less suitable as
template structure.
An important decision criterion to use CYP101 as the
template is also its spatial properties. When comparing its
active site cavity to that of the mammalian P450s, we
found that the steroidal ligands would not be able to ﬁt into
the active site cavity of the mammalian P450s with C11 and
C18 oriented to the heme, unless additional space is intro-
duced near helix K. Because the most important interac-
tions between protein and ligand take place near the heme,
the regions lining the active site must be modelled with the
highest accuracy. From the multiple sequence alignment
with the CYP11B family one can see that beta-sheet 6-1
following helix K possesses a 1 amino acid insertion in the
CYP101 structure and a 1 amino acid deletion in the
mammalian structures (Fig. 3). Although it is possible to
model this site through a deletion in the mammalian
structures, the resulting active site cavity would become
strained. Since the structure of CYP101 is elongated,
modelling a 1 amino acid insertion and relaxing the fold
will create a better deﬁnition of this active site region.
Taking into account that its substrate and reduction system
are similar to that of the CYP11B family, CYP101 is found
to possess the best structural core for the modelling of the
CYP11B isoforms.
Because the structural core of the cytochrome P450
enzyme structure is the four-helix bundle comprising the
helices D, E, I and L, and the two helices J and K, they
should all be taken from one and the same template
structure [43–45]. Hence, when taking the helices I and K
from CYP101, the other regions must be used as well.
Within the topological alignment of these regions, the
mammalian P450s contain insertions and deletions in the
connectivity between helix C and D, which is an additional
reason why we have decided to construct the CYP11B
models using the CYP101 structure.
Using the main structural features of CYP101, the
remaining variant regions of the P450 fold (helices B¢,F ,
G, J¢ and the meaner region) were modelled with CYP2C5.
CYP2C5 was chosen because after aligning the desired
structures, it was found to possess slightly better spatial
alignment with CYP101 than the other mammalian crystal
structures, and additionally, CYP2C5 is a steroid synthase
itself. Special attention was given to the modelling of helix
B¢ by CYP2C5 and its connection to the helices F and G.
This three helical complex makes up the entrance of the
active site cavity and closes the pocket like a lid. The helix
B¢ is predicted to be 3 turns long in the CYP11B family and
there is an apparent insertion of 3 residues compared to that
of the other cytochrome structures (Fig. 3). In the CYP101
structure, this helix is positioned too high in the active site
cavity, which is probably a reason why it is regularly seen
as inappropriate to model on. We chose the structure of
CYP2C5 where we extended its helix from a 2 turn length
to a 3 turn length.
The ﬁrst 50 N-terminal residues corresponding to the
membrane binding region of the human cytochrome 11B
family were omitted from the models because no comple-
mentary sequence is present in the crystal structures of
either CYP101 or CYP2C5. Some manual adjustments
were made to the hCYP11B2 model to compensate for
large steric hindrances and the model was reﬁned by
energy minimisation using a MOE succession method of
steepest descent, conjugate gradient and truncated newton
until an RMS gradient of 0.1 kcal/(mol A ˚) was reached.
The Charmm22 forceﬁeld [55] was used with a dielectric
constant of 4 and all backbone atoms were tethered with a
force constant of 100 kcal/(mol A ˚ 2) to prevent large
movements.
To investigate the inﬂuence of the triple mutant intro-
duced in the hCYP11B2 protein by Bottner et al. [36], a
hCYP11B2-triple mutant homology model (hCYP11B2-
TM) was created. The three dimensional architecture of
this structure should turn out to be similar to the active site
of hCYP11B1. Models for hCYP11B1, rCYP11B1 and
rCYP11B2 were also constructed by amino acid replace-
ment in the model of hCYP11B2, followed by a structural
relaxation of the fold with MOE.
The four ligands 11-deoxycorticosterone (DOC), corti-
costerone (B), 18-hydroxy-11-deoxycorticosterone (18OH-
DOC) and 18-hydroxycorticosterone (18OH-B) were ﬁt in
the active sites of all CYP11B models matching all three
CYP11B hydroxylation sites (C11,C 18,C 19) to the oxygen
atom occupying the 6th ligating position of the heme iron.
First the steroids were docked into the active site using
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123automated docking to get an impression of the relative
positioning of the C11,C 18 and C19 above the heme. Next,
alternate orientations of the steroids were investigated by
visual inspection, taking into account alternate folding of
amino acid side chains. A distance of 2.5 A ˚ was chosen as
a starting distance between the oxygen and carbon atoms,
which is a near-optimal distance for hydrogen atom
abstraction during hydroxylation [56]. A threshold of 5.0 A ˚
was estimated to be the representative maximal distance for
hydroxylation. The models were then equilibrated with
MOE without tethering the backbone atoms, allowing the
model active sites to diverge.
Ligand docking
The docking of all ligands was performed using GOLD
v3.0 [57], in order to investigate the protein-ligand inter-
actions and investigate the application of the models for
inhibitor potency prediction. The docking parameters used
were taken from the default 1 GOLD GA settings. These
settings were used for all docking runs presented in this
study. Each ligand was docked 5 times for 100 poses each
for which the GOLD Fitness score was obtained using the
standard Goldscore function. The amount of docking runs
and poses was taken to ensure an appropriate sampling of
the ligand conformations in the active site of the protein.
For the inhibitors, the ﬁtness score was averaged for the top
10 ranking poses if the conformation was within an RMSD
of 1.0 A ˚ from the best ranking pose (results Table 5).
Subsequently, to get an impression of the correlation of the
docking with the in vitro data, the Goldscore measure of
binding afﬁnity was calculated by the method reported by
Verdonk et al. [57] per DGbinding = –0.1075 * Goldscore–
2.2665 (R
2 = 0.5529, N = 60, DGbinding expressed in kcal/
mol). The average poses were also rescored with the
Chemscore scoring function [58].
Docking of steroids was performed in the presence of an
iron-bound oxygen atom and their conformations were
afterwards checked to investigate alternate orientations of
the steroid in the active site cavity. The protein structures
used for docking the substrates were the unequilibrated
structures, whereas for docking the inhibitors, the
hCYP11B1 and hCYP11B2 models were used after they
were equilibrated with the ligand 18-hydroxycorticoster-
one. All docking runs were performed in the absence of
water molecules. For each inhibitor, the best ranked pose
was used as input for the molecular dynamics study.
Molecular dynamics of inhibitors
Several molecular dynamics simulations were performed to
investigate the stability of the enzyme models of
hCYP11B1 and hCYP11B2, and the dynamic behaviour of
the three inhibitors inside the respective active sites. The
simulations were performed with the NAMD package [59]
using the Charmm22 forceﬁeld [55]. The protein models of
hCYP11B1 and hCYP11B2 were solvated in a
80 · 80 · 80 A ˚ equilibrated water box, removing any
overlapping water. Counter-ions were added to ensure an
overall net charge of zero. The protein-ligand complexes
were slightly equilibrated for 25 ps at a temperature of
100 K and were subsequently simulated for 1ns at a tem-
perature of 310 K in an NPT ensemble. All simulations
were carried out using periodic boundary conditions. To
calculate the electrostatic interactions we chose the
implementation of NAMDs Particle Mesh Ewald [60]. To
accommodate the ﬁlling of the active site cavity volume by
the three ligands, three and four explicit water molecules
were positioned in the active sites of hCYP11B1 and
hCYP11B2 respectively (volumes are hCYP11B1 360 A ˚ 3,
hCYP11B2 334 A ˚ 3, etomidate 269.7 A ˚ 3, fadrazole
241.9 A ˚ 3, metyrapone 247.7 A ˚ 3, water 15.5 A ˚ 3). The
positioned water molecules were optimised in the equili-
bration step.
Cellular assay for measuring inhibitor in vitro activity
For determining inhibitor potencies for CYP11B1 and
CYP11B2, an assay was used in which cells overexpressing
CYP11B1 or CYP11B2 convert the used steroid substrates
for these cytochromes into their products. Product forma-
tion rates were assessed by HPLC. V79 cells overex-
pressing CYP11B1 (stably transfected with a pcDNA3.1
vector, carrying a hygromycin resistance box) were con-
structed at NV Organon (Oss, the Netherlands). These cells
were constructed in the following manner. The full length
cDNA for human CYP11B1 was obtained by PCR from
human adrenal cDNA as described by Kawamoto et al [61]
and cloned into pPCR SCRIPT (Stratagene, La Jolla,
USA). After digestion with Xho I and Not I, the obtained
cDNA was inserted into a Xho I/Not I digested pcDNA3.1
vector (InVitrogen, Breda, Netherlands), carrying a hy-
gromycin resistance box. Following transfection to the V79
cells, positive cells were selected based on their hygro-
mycin resistance. The presence of the CYP11B1 gene was
conﬁrmed by PCR and the presence of 11b-hydroxylase
activity (i.e., the ability to produce corticosterone or cor-
tisol from 11-deoxycorticosterone or 11-deoxycortisol
respectively). Although no electron-transporting proteins
were co-transfected, the CYP11B1 expressing V79 cells
showed abundant 11b-hydroxylase activity, as was previ-
ously also shown by Denner et al. for both CYP11B1 and
CYP11B2 [62]. In normal (non transfected) V79 cells, no
detectable 11b-hydroxylase activity or PCR signals were
found. V79 cells stably (over)expressing CYP11B2 were
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123developed in the laboratory of Prof. R. Bernhardt, Institute
of Biochemistry, Saarland University, Saarbru ¨cken,
Germany [62–64].
Cells were cultured under standard conditions in
DMEM/FK12 medium (Gibco, Gaitersburg, USA) sup-
plemented with 10% foetal calf serum (Hyclone, Logan,
USA), penicillin/streptomycin (100 U/mL and 100 lg/mL,
respectively, Gibco), inside a humid environment of 37  C,
and 5%CO2 atmosphere. For assessing inhibitor potencies,
cells were transferred to 12 well plates and grown until
they were conﬂuent. Next, cells were incubated for 1 h in
serum-free medium with cumulative inhibitor concentra-
tions, followed by addition of 500 nM (0.5 times Km) 11-
deoxycorticosterone (Sigma-Aldrich, St Louis, USA) as
substrate. Finally, V79 CYP11B1 cells were incubated for
another 1 h and V79 CYP11B2 cells for another 3 h.
Medium was removed and the (produced) steroids were
extracted with 5 mL diethylether from 1 mL medium
aliquots, mixed with 1 mL 1 M sodium-glycine buffer (pH
10.5) containing 500 nM methylprednisolone (Sigma-Al-
drich) as internal standard. Extracts were dried under
nitrogen and dissolved in mobile phase for automated
HPLC analysis, using a stationary phase consisting of an
MR column (4.6 · 50 mm, particle size 2.5 lm) and a
mobile phase consisting of a mixture of 680/320/1 (v/v/v)
milliQ water, acetonitrile and triﬂuoro-acetic acid. Detec-
tion of UV absorption was performed at 243 nm (Shima-
dzu, Tokyo, Japan).
Results and discussion
Model quality
One of the theorems often applied to the quality assessment
of a protein model is the Ramachandran Plot, which is an
indicative measure for the correctness of the residue torsion
angles. The plot is a graphic display of torsion angle u
(Cn–1–Nn–Ca,n–Cn) versus torsion angle w (Nn–Ca,n–Cn–Nn+1)
for each residue of the protein of which the secondary
structure character of the residue can be extracted. The
alpha-helix character of a protein backbone is located
roughly in the region where –60  < u < –30  and
–120  < w < –30 , and the beta-sheet character is located
roughly in the region where –180  < u < –60  and
90  < w < 180  [65]. In Table 2, the results of the Rama-
chandran Plot are summarised for both hCYP11B1 and
hCYP11B2 models after they were equilibrated with the
ligand 18-hydroxycorticosterone.
For both hCYP11B1 and hCYP11B2 around 95% of the
residues are positioned in the favoured and core regions of
the Ramachandran Plot, indicating that for hybrid models,
the structures are of acceptable quality. Due to the high
quantity of alpha-helices and beta-sheets, the majority of
residues is positioned in the expected regions. The residues
which are situated in disallowed and unfavoured regions of
the plot, are located in loop regions outside the active site.
In total, 9 residues in the hCYP11B1 model are situated in
the disallowed regions and 15 residues in the unfavoured
regions. For the hCYP11B2 model, 10 residues are situated
in disallowed regions and 14 residues in the unfavoured
regions. The causes for these disparities are several inser-
tions or deletions introduced in the models for which the
structural minimisation was not sufﬁciently adequate to
correct the backbone dihedrals. In particular, these regions
are a relatively large insertion between alpha-helix D and
beta-sheet 3-1, and an insertion between helix G and H.
Additionally, the amino acid environment of the models
was evaluated with Errat [66] and Verify3D [67] (Table 2).
By comparing the results, it can be seen that the models all
score equally well but are less accurate than the template
structures. An Errat quality factor of 95% is expected for
crystal structures resolved at a resolution of 2.5 A ˚. Using
the Errat score per amino acid we were able to locate the
Table 2 Validation results for
the lowest energy models of
CYP11B1 and CYP11B2 and
the crystal structures which
were used for the template,
part I
a Outliers are positioned in
the loop regions before alpha-
helix F where the two template
structures connect and at the end
of alpha-helix D where a large
insertion was introduced
b Additional outliers are
positioned at the end of
alpha-helix G
Ramachandran Plot
(core regions)
(%)
Ramachandran Plot
(favourable regions)
(%)
Errat2
(quality
factor, %)
a
Verify 3D
(total
score)
b
Template (PDB, resolution)
CYP101 (2CPP, 1.63 A ˚) 92.1 100.0 96.0 197
CYP2C5 (1NR6, 2.10 A ˚) 87.8 99.2 93.6 195
Model
hCYP11B1 78.8 94.7 84.1 126
hCYP11B2 78.7 94.7 87.5 125
hCYP11B2-TripMut 80.6 96.5 81.1 117
rCYP11B1 79.7 96.5 80.2 113
rCYP11B2 82.4 96.5 80.1 114
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123deviations in the loop regions at the end of helix E where
our two template structures connect and at the end of helix
D where a large insertion was introduced. It is likely that in
the minimisation protocol with tethered heavy atoms, the
connectivity between template structures has not been fully
optimised. Investigation of the amino acid environment
with Verify3D resulted in similar conclusions as found
with Errat and the Ramachandran data. The low scoring of
Verify3D can be attributed to a bad folding of the regions
around the helices D and F, and additional potential errors
were located at the end of helix G, where again the two
templates have been connected to each other.
Finally, the stereochemistry of the models was analysed
with MOE (Table 3 [68]). Except for the already deter-
mined structural ﬂaws in the regions around helices D, F
and G, no additional ﬂaws were found using these mea-
surements, indicating that the overall fold of the protein is
of acceptable quality.
None of the structural ﬂaws are located at residues in the
active site or at residues lining the active site. The occur-
rence of Ramachandran errors and problems with model-
ling external loop regions seems an inevitable circumstance
in homology modelling [69, 70] and will probably not pose
a problem for modelling protein-ligand interactions. All the
abovementioned errors are expected to be alleviated during
further investigation of protein-ligand interactions using
molecular dynamics simulations. Therefore the current
models have been selected as appropriate starting points for
further analysis.
Protein-substrate interactions
After quality assessment of the created protein models
encompassing the various ligands, we investigated the
steroid binding mode. All docking results from GOLD
favoured the b-side of the steroid oriented to the heme with
the C3-carbonyl pointing towards alpha-helix B¢ (Fig. 4).
Visual inspection revealed that in case of reverse orienta-
tion of the steroid, unfavourable clashes of the C3-carbonyl
in the opposite side of the pocket would occur. After
docking the steroids into the active site, the protein–ligand
complexes were subjected to MOE minimisation as de-
scribed in the homology modelling section. After minimi-
sation, the distance between the heme iron atom and the
different substrate hydroxylation sites (C11,C 18 and C19)
was measured. The results are summarised in Table 4.
All ligands showed two very distinct interactions in the
modelled active site cavities. Firstly, the ligands possess a
steric ﬁt for the C20-carbonyl and the C21-hydroxyl in a
small cavity created between helix K and beta-sheet 6-1.
Inside this cavity, the C21-hydroxyl group possesses two
hydrogen bonding interactions with the protein backbones
of Gly379 and Phe381 (Fig. 4). The presence of these
amino acids in the active site cavity coincides with the
models of Belkina et al., but for those models, no inter-
actions between protein and ligand were discussed [34].
Secondly, the ligands possess an interaction between the
C3-carbonyl and active site residue Arg123 in helix B¢.
Arg123 is stabilised by Glu310 in helix I, which has further
Table 3 Validation results for the lowest energy models of CYP11B1 and CYP11B2 and the crystal structures which were used for the template,
part II
MOE-protein report Observed CYP101
(2CPP)
Observed CYP2C5
(1NR6)
Observed CYP11B1
model
Observed CYP11B2
model
Reference
values
a
Parameter Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D.
Trans-Omega 176.6 2.7 178.9 0.9 172.0 7.7 172.0 7.7 180.0 5.8
C-alpha chirality 32.8 3.6 34.3 1.7 30.8 11.1 30.8 10.8 33.8 4.2
Chi1-gauche minus –63.0 17.4 –63.3 14.8 –62.3 21.7 –62.6 22.1 –66.7 15.0
Chi1-gauche plus 55.4 20.7 56.3 16.4 51.5 26.7 53.0 28.3 64.1 15.7
Chi1-trans 185.3 13.3 184.2 12.9 186.3 21.9 186.8 20.3 183.6 16.8
Helix phi –65.2 11.9 –67.4 15.5 –60.7 19.7 –61.1 19.8 –65.3 11.9
Helix psi –41.2 16.5 –37.6 17.9 –42.5 25.1 –41.9 25.2 –39.4 11.3
Chi1-pooled S.D. 15.5 13.8 22.5 21.6 15.7
Proline phi –65.8 11.3 –61.9 9.5 –65.3 19.6 –67.6 20.5 –65.4 11.2
Dihedral outliers 0 4 15 17
Bond angle outliers 0 0 3 4
Bond length outliers 0 0 0 1
Results were generated with the MOE module: protein Eval. The thresholds were chosen to be 5 for the Z-Score and 70 for the vanderWaals
contacts
a Reference values were published in a statistical survey of the high-resolution data in the Protein Data Bank [68]
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123stabilising interactions with the protein backbone. Glu310
coincides with an aspartic acid in the CYP2 family which
from visual inspection of the crystal structures of CYP2C5
(pdb-code 1NR6) and CYP2C9 (pdb-code 1OG5) seems to
play a speciﬁc stabilising role in the active site structure; it
is expected that Glu310 has the same stabilising role. The
difference in chain length between an aspartic acid and a
glutamic acid also determines the ﬂexibility of helix B¢.I t
can move 1.5 A ˚ further out of the active site cavity in all
CYP11B models allowing the steroid to ﬁt parallel to the
heme. The ligands also possess many hydrophobic inter-
actions in this region, particularly with Phe130 (Fig. 4).
Due to the close interactions with the A and B rings of the
steroid skeleton, this amino acid might play an important
role in substrate stabilisation. The presence of Phe130 in
our models coincides with the models of Ulmschneider
et al. [35] where it is seemingly involved in ring stacking
with their inhibitors.
There are also two striking differences between the
CYP11B1 and CYP11B2 models. Firstly, the active site
cavity near beta-sheet 6-1 is smaller in both CYP11B2
models compared to the CYP11B1 models, with
rCYP11B1 being the largest. This small cavity is formed
by the loop region between helix K and beta-sheet 6-1
(Fig. 5). Comparing this cavity in both the hCYP11B1 and
hCYP11B2 models, we ﬁnd that in hCYP11B1 this cavity
has a 9–14% larger volume, dependent on amino acid
ﬂexibility as well as the probe radius chosen for calculation
of the volume (differing from 1.0 to 1.5 A ˚). This difference
in size is caused by the folding of Leu407 which induces a
1.0 A ˚ outward shift of the loop region. A comparison of the
models with the crystal structures of the CYP2 family re-
veals that the loop region in the CYP11B models is in
closer proximity to helix I (by 1.5 A ˚). This contact is de-
ﬁned by two amino acids having relatively smaller side-
chains (Pro322 and Val378 in CYP11B) than observed in
the CYP2C family (generally Thr/Val and Leu/Ile).
Changes in helix I such as the mutant A320V between
hCYP11B1 and hCYP11B2 are likely to have a direct
inﬂuence on the folding of this region.
Secondly, helix B¢ is shifted outward by 1.1 A ˚ in both
CYP11B2 models (the backbone RMSD of helix B¢ of
hCYP11B1 and hCYP11B2 is 2.13 A ˚). The change in
spatial positioning of this helix is probably caused by the
mutants L301P and E302D in helix I, but because this
region is on the surface of the protein, the exact cause is
less clear. In the hCYP11B2 model, Glu302 contacts
Fig. 4 Hypothetical binding of 18-hydroxycorticosterone (18OH-B)
inside the CYP11B2 active site for the synthesis of aldosterone. The
heme prosthetic group contains a bound oxygen atom needed for
catalytic function. The CYP11B2 model possesses Arg123 in alpha-
helix B¢ which is stabilised by Glu310 in alpha-helix I. 18OH-B
possesses several hydrogen bonds: one internal hydrogen bond
between the C18-hydroxyl and the C20-carbonyl, two hydrogen bonds
between the C21-hydroxyl and the backbone carbonyls of Gly379 and
Phe381, and ﬁnally a hydrogen bond between the C3-carbonyl and
Arg123
Table 4 Hydroxylation distance table (iron atom–carbon atom) after minimisation with MOE (distances in Angstrom)
hCYP11B2 hCYP11B2-TripMut HCYP11B1 rCYP11B1 rCYP11B2
C11 C18 C19 C11 C18 C19 C11 C18 C19 C11 C18 C19 C11 C18 C19
DOC 4.72 4.30 5.61 4.37 4.65 5.32 4.30 4.56 5.48 4.30 4.75 4.83 4.70 4.24 5.54
18OH-DOC 4.33 4.30 5.42
a 4.31 4.51 5.21
b 4.31 4.60 5.19
b 4.30 4.68 5.17
b 4.32 4.31 5.39
a
B 5.39 4.06 5.46 5.37 4.40 5.22 5.43 4.39 5.28 5.33 4.49 4.94 5.28 4.21 5.20
18OH-B 4.86 4.21 5.50
a 5.42 4.64 5.29
c 5.38 4.62 5.26
d 5.47 4.62 5.28
d 5.29 4.35 5.29
a
a Ligand C18-hydroxyl group forms a hydrogen bond with the C20-ketone group of the ligand
b Ligand C18-hydroxyl group forms a hydrogen bond with the iron-oxygen of the protein
c Ligand C18-hydroxyl group forms a hydrogen bond with the C11-hydroxyl group of the ligand
d Ligand C11-hydroxyl group forms a hydrogen bond with the C18-hydroxyl group of the ligand
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123helix B¢ at Lys127, which forms the counter charge for the
C-terminal end of this helix. Hasemann et al have posed
that movement of helices B¢, F and G is involved in the
opening of the active site cavity [71]. Changing the
stabilising environment of helix B¢ has a likely effect on
the structural stability of the helix and may result in a loss
of activity.
Introducing the triple mutant investigated by Bottner
et al. [36] by means of the hCYP11B2-TripMut model
showed that the hydroxylation distance pattern of the
substrates shifts as expected from hCYP11B2 to that of
hCYP11B1. Both hCYP11B1 and hCYP11B2-TM display
similar active site cavities near beta-sheet 6-1 (backbone
RMSD 1.43 A ˚) with only slight deviations in the hydrox-
ylation distances for the ligands (Table 4). This conﬁrms
the behaviour of the triple mutant in enzymatic activity
found by the study of Bottner et al. To speculate further,
Bottner et al have shown that the A320V mutant alone or
the L301P/E302D mutant alone, is not enough to signiﬁ-
cantly change aldosterone synthesis [36]. Only mutation in
both regions results in an almost complete loss of the
aldosterone synthesis capabilities of hCYP11B2. It is likely
that the subtle changes on both sides of the active site go
hand-in-hand to (nearly) completely convert the activity of
hCYP11B2 into that of hCYP11B1.
For DOC, our results indicate that hCYP11B1 and
rCYP11B1 preferentially catalyse C11-hydroxylation,
whereas hCYP11B2 and rCYP11B2 preferentially catalyse
C18-hydroxylation. For both CYP11B2 models, the shifted
alpha-helix B¢ causes DOC to present its C18 closest to the
iron as it is repositioned by the strong interaction of the C3-
carbonyl group with Arg123 in alpha-helix B¢. Addition-
ally, the larger active site of rCYP11B1 around beta-sheet
6-1 allows DOC to ﬁt further into the niche presenting C19
into hydroxylation range (distance less than 5.0 A ˚). A point
of argument against a preferred C18-hydroxylation of DOC
by CYP11B2 is that in vitro measurements indicate higher
levels of the C11-hydroxylated product B [19, 21]. How-
ever, both C11- and C18-hydroxylated products of DOC can
be promptly consumed as a substrate for the production of
18OH-B and subsequently aldosterone, in in vitro [19, 21].
This apparent discrepancy between observed and predicted
regioselectivity of DOC hydroxylation by CYP11B2 may
possibly indicate that other factors than hydroxylation
distances are involved in the formation of the actual
products.
For 18OH-DOC, the C18-hydroxyl group forms a
hydrogen bond with the iron–oxygen limiting hydroxyl-
ation to C11 which is in closest proximity to the iron. In the
CYP11B2 models both C11 and C18 are in approximately
equal distance to the iron and an internal hydrogen bond is
formed by the substrate between the C18-hydroxyl group
and the C20-carbonyl. Although both C11- and C18-
hydroxylation are shown to be possible in such a complex,
oxidation on the unsubstituted C11 is likely to form a more
stable reaction intermediate.
In all models, the two C11-hydroxylated ligands B and
18OH-B only portray C18 in close proximity to the iron, as
the C11-hydroxyl group blocks access of C11 to the heme
iron. The positioning of the C18-hydroxyl group of 18OH-B
in the active site cavity appears to determine conversion
into aldosterone. In both CYP11B2 models, the natural
substrate is shifted above the heme, which creates a slightly
larger active site cavity near beta-sheet 6-1 for the C18-
hydroxyl group to rotate in. This difference in size allows
room for an internal hydrogen bond between the C18-hy-
droxyl group and the C20-carbonyl for both 18OH-DOC
and 18OH-B. In rCYP11B1 and hCYP11B1, the C18-hy-
droxyl group forms a hydrogen bond with the heme oxygen
atom which blocks C18 for hydroxylation (Fig. 4). Inter-
estingly, in the hCYP11B2-TripMut, the C18-hydroxyl
group forms an internal hydrogen bond with the C11-hy-
droxyl group, and thereby also blocks the C18 for
hydroxylation.
In conclusion, we propose that the immediate folding of
the active site around the substrate C18-hydroxyl group
may be the key difference between the two isoforms
leading to the production of aldosterone by CYP11B2 and
Fig. 5 Active site volume difference between the hCYP11B1 (white)
and hCYP11B2 models (orange). Shown for both hCYP11B1 and
hCYP11B2 are the active site volume and the backbone trace.
R-fadrazole and S-fadrazole are indicated with blue and purple
respectively. It is clear to see that hCYP11B1 contains a larger active
site between helix I and sheet 6-1. This cavity allows S-fadrazole to ﬁt
the cavity, but not R-fadrazole (black arrow). On the other side of the
active site near Helix B¢ and Arg123, hCYP11B2 contains the larger
cavity, which might rationalise the better ﬁt of R-fadrazole in the
cavity
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123not by CYP11B1. To speculate further on the mechanism
of the enzymatic formation of aldosterone from 18OH-B,
we hypothesise that a stable internal hydrogen bond for the
C18-hydroxyl group of the ligand may be essential to sta-
bilise its C18 against further oxidation. A second oxygen
atom can then be inserted between C18 and one of its
hydrogen atoms, forming a C18-gem-diol intermediate
which forms aldosterone by elimination of water. Although
the formation of a C18-gem-diol has been proposed by
Johnston et al. [72], the precise mechanism of oxidation is
still unknown. This proposed method of substrate stabili-
sation may explain the regioselectivity of the two CYP11B
isoforms and can be attributed to the subtle changes
observed on two sides of the active site cavity; the cavity
near helix K and the positioning of helix B¢.
Protein-inhibitor interactions
The non-steroidal inhibitors, metyrapone, R-etomidate,
R-fadrazole and S-fadrazole were docked ﬂexibly into the
active site of the human CYP11B models where their
aromatic nitrogen atom forms a strong interaction with the
sixth ligating position of the heme iron atom. The acces-
sible electron lone pair of the heterocyclic nitrogen atom is
required for heme iron complexation, a well-known inter-
action for non-steroidal CYP inhibitors [73, 74].
The GOLD docking results showed all ligands to bind in
one favourable conformation. The enantiomers R-fadrazole
and S-fadrazole mainly favoured one particular orientation
in the active site cavities of hCYP11B2 and hCYP11B1
respectively. The higher afﬁnity of S-fadrazole to
hCYP11B1 and R-fadrazole to hCYP11B2 can be attrib-
uted to the active site difference near beta-sheet 6-1 and
helix I (Fig. 5). The difference in afﬁnity is determined by
the steric aspects of the active site cavity allowing only
S-fadrazole to ﬁt in the active site of hCYP11B1, where
R-fadrazole possesses a steric clash (black arrow). In
hCYP11B2, it is less clear why R-fadrazole ﬁts the active
site best, but this is mainly determined by steric effects
near helix B¢. Due to the presence of rotatable bonds,
R-etomidate was able to dock in different orientations, but
favoured one particular conformation with its phenyl ring
pointing into the direction of helix B¢. The main ﬂexibility
observed was caused by the ethyl-ester group and the
docking score of those conformations was very similar.
Metyrapone was able to dock with both pyridine rings to
the iron, but mainly favoured a conformation with the
carbonyl facing Arg110. Since all ligands favoured only
one orientation, it was this orientation that was investigated
by MD.
Our in vitro test results show a striking enantioselec-
tivity of fadrazole binding for the CYP11B family. We ﬁnd
R-fadrazole to be the most active enantiomer for CYP11B2
as well as being selective (Table 5). In contrast, for
CYP11B1 it is S-fadrazole which appears to be the most
potent enantiomer. A similar stereoselectivity as for
CYP11B1 has also been described for aromatase, wwith
the S-enantiomer being the better aromatase inhibitor [75].
The docking results from both Goldscore and Chemscore
predict the same enantioselectivity for fadrazole in the
CYP11B family as observed in vitro, indicating that the
three dimensional models contain promising accuracy
for the valid prediction of enantiomer selectivity. Dock-
ing results of the two other inhibitors metyrapone and
R-etomidate conﬁrm the trend of inhibitor potency as
determined by the in vitro experiments (Table 5).
Our human CYP11B1 and CYP11B2 models are able to
rationalise the (inverse) enantioselectivity of CYP11B1
and CYP11B2 inhibition by fadrazole as observed in the
in vitro tests. The enantioselectivity can be attributed to the
small cavity size differences of the models. Both enantio-
mers bind with a steric ﬁt comparable to the A, B and C
Table 5 Correlation of docking and molecular dynamics results to in vitro data for both human CYP11B1 and CYP11B2 models
IC50 (nM) Goldscore DG Goldscore (kcal/mol) DG Chemscore (kcal/mol) Unon-bonded (kcal/mol)
hCYP11B1
Metyrapone 46.4 ± 10.4 57.33 –8.43 –8.73 –48.4 ± 3.7
R-Etomidate 0.5 ± 0.2 66.21 –9.38 –9.25 –56.0 ± 2.4
R-Fadrazole 118.6 ± 8.9 54.01 –8.07 –8.14 –38.4 ± 2.5
S-Fadrazole 39.5 ± 4.4 56.67 –8.36 –8.77 –56.3 ± 3.4
hCYP11B2
Metyrapone 207.8 ± 4.5 49.99 –7.64 –7.95 –36.2 ± 7.5
R-Etomidate 1.7 ± 0.9 65.21 –9.28 –9.21 –54.4 ± 2.9
R-Fadrazole 6.0 ± 1.9 63.20 –9.06 –9.38 –55.9 ± 3.3
S-Fadrazole 171.2 ± 51.7 53.81 –8.05 –8.12 –44.3 ± 1.8
Indicated are the Goldscore and the extracted Goldscore binding free energy as well as the Chemscore binding free energy. Unon-bonded indicates
the total non-bonded energies between the protein and the ligand for the molecular dynamics simulations
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123rings of the endogenous substrates, where the cyanobenzyl
moiety forms a p–p stacking interaction with Phe130. In
addition to the steric interactions, both enantiomers possess
a strong polar interaction between their cyanide moiety and
Arg123, mimicking the interaction that the C3-carbonyl of
the natural substrates possesses with this amino acid.
Metyrapone was not found to possess any hydrogen
bonding or polar interaction with the active site other than
the aromatic nitrogen. Instead it possesses a pronounced
steric ﬁt with its second aromatic ring overlapping the
space occupied by the A-ring in case of the steroidal sub-
strate. R-etomidate, which was not designed as a CYP11B
speciﬁc inhibitor, does possess a hydrogen bonding inter-
action. The hydrogen bond is made between its ester
moiety and the catalytic Thr318, and is present in both
hCYP11B1 and hCYP11B2. This may explain the non-
selective inhibitory action of R-etomidate on both isoforms.
Its aromatic phenyl ring also possesses strong steric inter-
actions, overlapping the same space of the steroidal A-ring
like metyrapone.
Molecular dynamics
Given the promising prediction of the models for substrate
conversion, substrate binding, inhibitor binding and the
satisfying Ramachandran Plots, we conducted molecular
dynamics simulations to obtain a better understanding of
the dynamic behaviour of the inhibitors in the active site of
the enzyme models. To investigate the structural integrity
change during the simulation, we calculated the relative
root mean square deviation (RMSD) over all heavy atoms
(Fig. 6).
During the ﬁrst 500 ps, the RMSD increased and the
protein still adapted towards its optimal conformation.
After this point in time hardly any change in the three
dimensional structures of the proteins was observed. The
largest ﬂuctuations of the protein were found in the ﬂexible
regions with peak values located in the structures around
alpha-helix D (not shown). In the random coil following
alpha-helix D we introduced a large insertion of seven
amino acids, which elongates the alpha-helix by one turn
before it connects to the following beta-sheet. Inside the
water box, this region is found to protrude into the water
without any stabilising protein interactions and unfolds due
to interaction with water. In all the simulations we ob-
served an opening of the active site and the continuous ﬂow
of water molecules in and out of the active site cavity.
Several water molecules retained key positions, such as the
water molecules that make up the channel towards the
conserved Glu459 (not shown).
All the inhibitors maintained the same interactions as
observed in the docking study. In Fig. 7, the resulting poses
of the inhibitors metyrapone and R-etomidate are displayed.
Both possess a ring stacking with Phe130 in the active site,
and R-etomidate also possesses a hydrogen bond with
Thr318. Arg110 stabilises the heme in the active site. In
Fig. 8, the poses of R-fadrazole in the CYP11B2 active site
and S-fadrazole in the CYP11B1 active site are compared.
Here it can be seen that in the CYP11B2 model, alpha-helix
B¢ is moved further out of the active site. In the CYP11B2
model, Arg123 possesses a polar interaction with Glu310,
whereas Phe130 provides a horizontal ring stacking for
R-fadrazole. In the CYP11B1 model, S-fadrazole possesses
the same interactions with the protein, although the ring
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Fig. 6 RMSD for the molecular
dynamics simulations of the
different protein-ligand
complexes of the hCYP11B1
and hCYP11B2 models.
Metyrapone is coloured black,
R-etomidate green, R-fadrazole
red, and S-fadrazole blue
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123stacking with Phe130 is vertical rather than horizontal.
Importantly, the interaction points of the fadrazole enanti-
omers and those of the natural substrate coincide very well.
R-fadrazole and S-fadrazole displayed different behav-
iour in the other protein models. R-fadrazole lost its direct
interaction with the heme iron atom in the hCYP11B1
model, exchanged it for a water molecule and drifted to the
top of the active site. S-fadrazole displayed a similar
behaviour in the hCYP11B2 model. Repeated simulations
did not change either scenario, indicating that unlike the
eutomers, the distomers do not comfortably ﬁt our starting
models.
Because the complex was stable over the last 500 ps,
we sampled the non-bonded interactions between the
protein and the ligand for this time period (Table 5).
These interactions contribute to the binding free energy,
although the solvation effects of free ligand still need to
be subtracted [76]. These energies follow the same gen-
eric trend which emphasise the strong interactions for
R-etomidate in both hCYP11B models and the strong
interactions of S-fadrazole in hCYP11B1 and R-fadrazole
in hCYP11B2 respectively.
Conclusion
We have constructed homology models of the two isoforms
of the human CYP11B family, as well as promising starting
models for the rat isoforms. These models are based on the
knowledge of substrate speciﬁcity, which were deﬁned as
the differences in hydroxylation distances between the
active site and the C11,C 18 and C19 of the steroid skeleton.
As both hCYP11B1 and hCYP11B2 possess virtually
similar active sites, the steric ﬁt of the different steroidal
ligands seems to be one of the strongest determinants for
substrate speciﬁcity.
We have found that within the active site of the
hCYP11B2 model, the endogenous ligand 18-hydroxy-
corticosterone forms a stabilising internal hydrogen bond.
This is not observed for the hCYP11B1 model, which
might rationalise why 18-hydroxycorticosterone is solely
a substrate for CYP11B2 to yield aldosterone. In addi-
tion, the interactions of the C3-carbonyl with Arg123 in
alpha-helix B¢, the interaction of the C21-hydroxyl with
the backbones of Gly379 and Phe381, and the presence
of Phe130 are also important for the stabilisation of the
ligand in the protein active site. Determinant for the
interaction of Arg123 is the presence of Glu310 in alpha-
helix I, which stabilises Arg123 and alpha-helix B¢ in the
active site.
The known non-steroidal CYP11B inhibitors metyra-
pone, R-etomidate, R-fadrazole and S-fadrazole were pos-
tulated to occupy the same space in the active site as the
endogenous substrates. Conclusions from both molecular
docking and molecular dynamics simulations corroborate
the measured activity data from in vitro experiments,
Fig. 7 CYP11B2 active site model with metyrapone (purple) and R-
etomidate (blue) in the active site. Indicated are the stabilising
interaction between Arg110 and the heme, as well as Phe130 which
accommodates a ring stacking with the ligands. The ester group of R-
etomidate possesses a hydrogen bond with Thr318
Fig. 8 CYP11B1 model (orange) containing S-fadrazole (purple) in
the active site and CYP11B2 model (white) containing R-fadrazole
(blue) in the active site. Indicated, the stabilising interaction between
Arg110 and the heme, as well as the stabilising hydrogen bonds
between Arg123 and Glu310. Phe130 accommodates a ring stacking
with the fadrazole enantiomers; horizontally for the R-enantiomer and
vertically for the S-enantiomer
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123supporting the validity of the constructed models for these
ligands. Importantly, these models rationalise the enanti-
oselectivity of fadrazole, with the R-enantiomer being most
potent on CYP11B2 and the S-enantiomer being most
potent in CYP11B1.
The constructed models are useful tools in trying to
understand some of the molecular mechanisms involved
in ligand binding and substrate conversion for the
CYP11B family. As such, these models might also be
appropriate tools for more detailed protein-inhibitor
modelling studies as well as for ligand design or database
screening, following further model optimisation and
model tuning.
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